Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORL-1M in CDG-Ib
NCT03404869Phase 2Unknown
- Sponsor
- Orpha Labs
- Start
- Mar 2015
- Primary completion
- Jun 2019
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in congenital disorder of glycosylation type Ib (CDG-Ib), sponsored by Orpha Labs. Primary endpoint: Improvement in hypoglycemia, diarrhea and vomiting at 6 months. Status: unknown.
02
Conditions
congenital disorder of glycosylation type Ib (CDG-Ib)
Beyond the preview
Go deeper on NCT03404869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03404869.